AGBL3 and rheumatoid arthritis: However, in participants with baseline anti-CCP3 levels of <=60, while the survival curves visually differed, there were no significant differences in IA/RA incidence between those who developed dual positivity for RF-IgA and RF-IgM (Figure 1E).